Safety and Pharmacovigilance

Safety writing converts individual cases and aggregate data into information that supports detection, evaluation, minimization, and communication of risk. Applicable law, authority guidance, controlled terminology, product reference information, safety-system procedures, privacy rules, templates, data-lock processes, and medical governance all matter.

Individual case narratives

A case narrative reconstructs a clinically meaningful chronology from source data. It typically connects patient characteristics, medical history, indication, exposure, event onset and course, investigations, treatment, dechallenge or rechallenge, outcome, reporter or investigator assessment, company assessment, confounders, and follow-up as applicable.

The narrative should be selective without being selective about risk. Include facts needed to understand seriousness, expectedness, causality, clinical course, and alternative explanations. Do not fill gaps with plausible detail. Mark unknowns according to procedure and route inconsistencies for data clarification.

Control points:

• use the correct case, product, event, date, and coding identities;
• preserve chronology and distinguish report dates from clinical dates;
• reconcile structured fields, line listings, source documents, and narrative;
• separate reporter opinion, investigator opinion, sponsor assessment, and writer inference;
• protect personal information;
• handle follow-up and version changes through the controlled safety system;
• use medical review for clinical interpretation.

Aggregate and periodic reports

Aggregate safety documents integrate interval data, cumulative exposure, case patterns, studies, literature, regulatory actions, signals, risks, effectiveness of risk minimization, and benefit-risk evaluation according to the report type. The writer needs a source and responsibility matrix because contributions arrive from multiple functions and data cuts.

State the reporting interval and data lock clearly. Reconcile denominators and exposure estimates. Separate new interval information from cumulative knowledge. Explain changes in signals and important identified or potential risks. Ensure actions and conclusions follow the evidence and are consistent with risk-management and reference safety information.

The summary must not conceal complexity that changes the benefit-risk view. Tables and appendices should support navigation and verification rather than act as an alternative to interpretation.

Risk-management documents

Risk-management writing links the safety specification to pharmacovigilance activities and risk-minimization measures. Each important risk or missing-information category needs a clear rationale, evidence base, planned activity, objective, implementation, and evaluation approach as applicable.

Maintain alignment across safety reports, product information, investigator materials, educational materials, and regulatory commitments. When the classification or understanding of a risk changes, trace the effect across the document ecosystem.

Safety-writing QC card

Check case counts, coding, event and product terms, seriousness, expectedness, causality language, dates, exposure, intervals, data cutoffs, reference information, signal status, risk classification, actions, and cross-document consistency. Run a dedicated privacy pass. Safety prose requires scientific clarity, but controlled data identity and procedural compliance come first.